South Korea: Samsung Biologics completes Biogen stake in Samsung Bioepis

Korea-listed fully integrated CDMO, Samsung Biologics, has completed the purchase of Biogen’s stake in the Samsung Bioepis joint venture for US$2.3bn. With the completion of the first payment of US$1bn pursuant to the terms of the acquisition agreement, Samsung Biologics has fully acquired Samsung Bioepis as a wholly owned subsidiary. The remaining US$1.3bn will be made in…

You must be a HMI Subscriber to view this content.

Subscribe Now »